Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
  • A61K38/2006—IL-1
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/76—Viruses; Subviral particles; Bacteriophages
  • A61K35/761—Adenovirus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/545—IL-1
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
  • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

• Applicant asserts that the information recorded in the form of an Annex C/ST.25 text file submitted under Rule 13fer.1 (a), entitled CALIM _16_02_PCT_Sequence_Listing_ST25.txt, is identical to that forming part of the international application as filed. The content of the sequence listing is incorporated herein by reference in its entirety.
• the present invention relates to gene therapy and compositions for gene therapy, more particularly to recombinant self-complementary adeno-associated virus (sc-rAAV) and methods of treating conditions or symptoms of conditions using sc-rAAV.
• sc-rAAV self-complementary adeno-associated virus
• Osteoarthritis affects over 27 million Americans and is the leading cause of disability among the elderly. Patients with OA are also at higher risk of death. The cost of OA to our health care system is estimated to be over $100 billion per annum. Such statistics reflect the fact that OA is both incurable and remarkably resistant to treatment.
• Non-pharmacological therapy includes a range of strategies such as patient education and self-help, exercise programs and weight loss.
• Pharmacological therapy includes the use of acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opiates and the intra-articular injection of glucocorticoids or hyaluronic acid.
• NSAIDs bring partial relief to many patients, but are associated with upper Gl bleeding and kidney failure, of especial concern in the present context as many individuals with OA are elderly.
• the intraarticular injection of glucocorticoids brings rapid relief in many cases, but the effects usually persist for only a few weeks. Repeated injection of glucocorticoids is impractical and counter-indicated because of concerns about infection and evidence that sustained, high doses of glucocorticoids damage articular cartilage.
• the benefits of the intraarticular injection of hyaluronic acid (viscosupplementation) are disputed; the ACR makes no recommendation on this score, while the AAOS no longer recommends it.
• MSCs mesenchymal stem cells
• autologous blood products such as platelet-rich plasma
• the latest recommendations from the Osteoarthritis Research Society International and European League against Rheumatism for treatment of OA of the knee do not differ greatly from those of the ACR and AAOS.
• the recommendations of the various bodies highlight the paucity of treatment options for OA and the complete lack of reliably effective pharmacologic interventions. Even when there is some response to therapy, it addresses only the signs and symptoms, not disease progression. When treatment fails to control the symptoms and progression of OA, surgical intervention may be indicated.
• IL-1 is a powerful mediator of both chondrocytic chondrolysis and suppression of matrix synthesis by chondrocytes. Together, these two processes are highly destructive to cartilage. IL-1 has also been shown to inhibit chondrogenesis but at the same time promote certain aspects of the osteogenic differentiation that could help account for the formation of osteophytes and sclerosis of sub-chondral bone. Paradoxically, IL-1 also promotes osteoclastic activity. By stimulating both osteogenesis and osteolysis, IL-1 would enhance bone turnover, as seen in the subchondral bone during OA. Finally, IL-1 is well positioned to provoke the inflammatory changes seen in OA. Its pyrogenic activities are known and the expression of vanishingly small amounts of IL-1 in the knee joints of rabbits is sufficient to elicit a pronounced synovitis.
• Targeted drug delivery is a major problem for the intra-articular treatment of joint diseases. Molecules of all sizes, as well as particles, are rapidly removed from joints via the lymphatics, subsynovial capillaries, or both. This makes it difficult to achieve sustained, therapeutic doses of anti-OA drugs in joints. To address this, small molecules can be delivered systemically, but proteins are difficult to deliver in this fashion because of size-dependent constraints in crossing the fenestrated endothelium of the synovial capillaries. Moreover, systemic delivery exposes non- target sites to high doses of the therapeutic, leading to unwanted side-effects. The rapid egress of proteins from joints, with half-lives typically of a few hours, makes intra-articular delivery potentially ineffective.
• recombinant IL-1 Ra (Kineret, Amgen Biologicals) is delivered by daily subcutaneous injection in effort to treat symptoms of RA.
• daily delivery fails to maintain therapeutic serum levels of IL-1 Ra between injections (Evans et al., 1996, Human Gene Therapy, 7:1261-1290; Evans et al., 2005, PNAS 102 (24): 8698-8703).
• Some studies have used ex vivo gene transfer for introducing IL-1 Ra to treat OA. However, these approaches are laborious and have not seemed to provide long-term gene expression (Frisbie et al., 2002, Gene Therapy 9(1 ): 12-20).
• these peptides require repeated systemic introduction (e.g., 4 doses every 2 weeks or 3 doses every 4 weeks, e.g., by subcutaneous injection or intravenous infusion) because of the relatively short half-life (Wang et al., 2015, Osteoarthritis and Cartilage 23:A398-399; Wang et al., 2014, Osteoarthritis and cartilage 22:S462-S463; Evans et al., 2005, PNAS 102 (24): 8698-8703).
• the present invention features methods and compositions for delivering a therapeutic gene product (e.g., IL-1 Ra) in a sustained manner to a location of interest, e.g., joints.
• a therapeutic gene product e.g., IL-1 Ra
• the present invention also features methods and compositions for treating symptoms of conditions such as but not limited to osteoarthritis and rheumatoid arthritis.
• the present invention also features methods and compositions for providing an individual (e.g., a human) a therapeutically effective amount of a therapeutic gene product (e.g., IL-1 Ra).
• the methods and compositions may feature a recombinant self-complementary adeno-associated virus (sc-rAAV), wherein the sc-rAAV comprises an engineered capsid and a vector (e.g., a sc-rAAV vector) packaged within the capsid.
• the vector may comprise a transgene (e.g., a nucleotide sequence encoding a protein of interest, e.g., a therapeutic gene product, e.g., IL-1 Ra or a codon modified version thereof) operably linked to a promoter (e.g., a constitutive promoter).
• the therapeutic gene product may be delivered to a location of interest, e.g., a joint.
• the sc-rAAV may be introduced into cells (e.g., chondrocytes, synoviocytes, etc.) in a joint via direct intraarticular injection.
• cells e.g., chondrocytes, synoviocytes, etc.
• the present invention is not limited to the aforementioned conditions, nor the location of interest (e.g., joint).
• Goodrich et al. (Molecular Therapy-Nucleic Acids, 2013, 2:e70) generally discloses a method of treating osteoarthritis using scAAV-delivered IL-1 Ra.
• Goodrich et al. does not specifically identify or enable any particular IL-1 Ra sequence, e.g., an IL-1 Ra sequence according to the present invention.
• the field of gene therapy is an unpredictable area wherein one cannot assume that any particular gene sequence for a protein of interest will be efficiently expressed.
• gene therapy is also unpredictable with respect to effectiveness in animal model compared to humans, e.g., one cannot assume that if a particular method is effective in an animal model that it will be effective in humans.
• the present invention features a recombinant self-complementary adeno- associated virus (sc-rAAV).
• the sc-rAAV comprises an engineered AAV capsid and a vector packaged within the capsid, wherein the vector comprises a modified IL-1 Ra gene operably linked to a promoter and the modified IL-1 Ra gene is at least 95% identical to SEQ ID NO: 2.
• the promoter comprises a CMV promoter.
• the engineered capsid comprises at least a portion of serotype AAV2 and at least a portion of serotype AAV6.
• the engineered capsid comprises at least a portion of serotype AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV1 1 , or a combination thereof.
• the vector further comprises SV40 and bovine growth hormone (bGH) polyadenylation sequences.
• the vector further comprises SV40 splice donor (SD) and splice acceptor (SA) sites.
• the vector comprises sc-rAAV2.5Hu-IL- 1 Ra.
• the sc-rAAV is part of a composition.
• the sc-rAAV comprises an engineered AAV capsid and a vector packaged within the capsid, wherein the vector comprises a modified IL-1 Ra gene operably linked to a promoter and the modified IL-1 Ra gene encodes IL-1 Ra protein according to SEQ ID NO: 6.
• the present invention features a method of providing a human in need thereof (e.g., a human diagnosed with or at risk for osteoarthritis or rheumatoid arthritis) a therapeutically effective amount of interleukin-1 receptor agonist (IL-1 Ra) peptide.
• the method comprises introducing into a location of interest (e.g., via intraarticular injection) a composition comprising a recombinant self-complementary adeno-associated virus (sc-rAAV) according to the present invention.
• the sc-rAAV transduces the vector into cells in the location of interest, wherein the modified IL-1 Ra gene is expressed so as to provide the human with the therapeutically effective amount of said IL-1 Ra peptide.
• the present invention also features a method of ameliorating symptoms of osteoarthritis or rheumatoid arthritis in a human.
• the method comprises introducing into a location of interest (e.g., via direct intraarticular injection) a composition comprising a recombinant self-complementary adeno- associated virus (sc-rAAV) according to the present invention.
• sc-rAAV self-complementary adeno- associated virus
• the sc-rAAV transduces the vector into cells in the location of interest, wherein the modified IL- 1 Ra gene is expressed so as to provide the human with an amount of IL-1 Ra peptide effective for ameliorating symptoms associated with osteoarthritis or rheumatoid arthritis.
• the present invention also features a method of repairing cartilage in a human in need thereof (e.g., a human diagnosed with or at risk for developing osteoarthritis or rheumatoid arthritis).
• the method comprises introducing into a location of cartilage (e.g., via direct intraarticular injection) a composition comprising a recombinant self-complementary adeno-associated virus (sc-rAAV) according to the present invention.
• the sc-rAAV transduces the vector into cells in the location of cartilage, wherein the modified IL-1 Ra gene is expressed so as to provide the human with IL-1 Ra peptide effective for repairing cartilage.
• the present invention also features a method of providing interleukin-1 receptor agonist (IL-1 Ra) peptide to an area of inflammation.
• the method comprises introducing into a location of inflammation (e.g., via intraarticular injection) a composition comprising a recombinant self-complementary adeno-associated virus (sc-rAAV) according to the present invention.
• sc-rAAV self-complementary adeno-associated virus
• the sc-rAAV transduces the vector into cells in the location of inflammation, wherein the modified IL-1 Ra gene is expressed so as to provide the cells in the location of inflammation a therapeutically effective amount of IL-1 Ra peptide effective for reducing inflammation.
• the location of interest is a joint, synovium, subsynovium, joint capsule, tendon, ligament, cartilage, or peri-articular muscle of the human.
• the cells are chondrocytes, synoviocytes, or a combination thereof.
• the method is performed a second time at a time point after a time when the method is performed first. In some embodiments, the time point is at least 3 months. In some embodiments, the method further comprises co-introducing a secondary therapy (e.g., a glucocorticoid, hyaluronan, platelet-rich plasma, recombinant, human IL-1 Ra, or a combination thereof) to the location of interest in combination with the composition.
• a secondary therapy e.g., a glucocorticoid, hyaluronan, platelet-rich plasma, recombinant, human IL-1 Ra, or a combination thereof
• the present invention also features a method of delivering IL-1 Ra peptide to a chondrocyte or synoviocyte.
• the method comprises contacting the chondrocyte or synoviocyte with a recombinant self-complementary adeno-associated virus (sc-rAAV) according to the present invention, e.g., an engineered adeno-associated virus (AAV) capsid comprising at least a portion of serotype 2 and at least a portion of serotype 6 and a vector packaged within the capsid, wherein the vector comprises a modified IL-1 Ra gene operably linked to a CMV promoter and the modified IL-1 Ra gene is at least 95% identical to SEQ ID NO: 2.
• the sc-rAAV transduces the vector into the chondrocyte or synoviocyte and the modified IL-1 Ra gene is expressed to as to provide IL-1 Ra peptide to the chondrocyte or synoviocyte.
• the modified IL-1 Ra gene may be at least 95% identical SEQ ID NO: 2 and
• FIG. 1 shows Plasmid sc-rAAV2.5Hu-IL-1 Ra, which contains a modified cDNA encoding the human IL-1 Ra protein under control of the CMV promoter.
• the gene insert also contains SV40 and bovine growth hormone (bGH) polyadenylation sequences, as well as SV40 splice donor (SD) and splice acceptor (SA) sites.
• bGH bovine growth hormone
• SD SV40 splice donor
• SA splice acceptor
• Adeno-associated virus AAV
• Recombinant AAV rAAV
• Recombinant Self-Complementary AAV sc-rAAV
• AAV is a small virus (20 nm) in the family Parvoviridae. AAV is not known to cause disease. AAV has recently been used to gene therapy for a variety of reasons including that it has been shown to have low immunogenicity, the ability to effectively transduce non-dividing cells, and the ability to infect a variety of cell and tissue types.
• Recombinant AAV rAAV
• Recombinant AAV DNA is packaged into the viral capsid as a single stranded molecule about 4600 nucleotides in length.
• sc-rAAV Self-complementary AAV
• sc-rAAV is an engineered form of rAAV that can form an intra-molecular double stranded DNA template.
• Expression The translation of a nucleic acid sequence into a protein. Proteins may be expressed and remain intracellular, become a component of the cell surface membrane, or be secreted into the extracellular matrix or medium.
• a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
• a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
• Pharmaceutically acceptable vehicles may be conventional but are not limited to conventional vehicles.
• Pharmaceutically acceptable carriers vehicles
• e.g., solutions may be conventional but are not limited to conventional vehicles.
• E. W. Martin Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 15th Edition (1975) and D. B. Troy, ed. Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, Baltimore MD and Philadelphia, PA, 21 st Edition (2006) describe compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compounds or molecules.
• the nature of the carrier will depend on the particular mode of administration being employed.
• compositions administered may contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
• non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
• Sequence identity The identity (or similarity) between two or more nucleic acid sequences is expressed in terms of the identity or similarity between the sequences. Sequence identity can be measured in terms of percentage identity; the higher the percentage, the more identical the sequences are.
• Sequence similarity can be measured in terms of percentage similarity (which takes into account conservative amino acid substitutions); the higher the percentage, the more similar the sequences are.
• Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, Adv. Appl. Math. 2:482, 1981 ; Needleman & Wunsch, J. Mol. Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp, CABIOS 5:151-3, 1989; Corpet et al., Nuc. Acids Res.
• NCBI National Center for Biotechnology
• BLASTN may be used to compare nucleic acid sequences
• BLASTP may be used to compare amino acid sequences. If the two compared sequences share homology, then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences.
• the BLAST-like alignment tool may also be used to compare nucleic acid sequences (Kent, Genome Res. 12:656-664, 2002).
• BLAT is available from several sources, including Kent Informatics (Santa Cruz, CA) and on the Internet (genome.ucsc.edu).
• the percent sequence identity value is rounded to the nearest tenth.
• Therapeutically effective amount A quantity of a specified agent sufficient to achieve a desired effect in a subject being treated with that agent.
• agents may include IL-1 Ra.
• a therapeutically effective amount of IL-1 Ra may be an amount sufficient to prevent, treat, or ameliorate symptoms of osteoarthritis or rheumatoid arthritis.
• the therapeutically effective amount of an agent useful for preventing, ameliorating, and/or treating a subject will be dependent on the subject being treated, the type and severity of the affliction, and the manner of administration of the therapeutic composition.
• transduced is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques.
• transduction encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viruses or viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration. Such cells are sometimes called transformed cells.
• Vector A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell.
• a vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
• a vector may lack the nucleic acid sequences that permit it to replicate in a host cell.
• a vector may also include a gene of interest, one or more selectable marker genes, other genetic elements known in the art, or any other appropriate insert.
• the present invention features methods and compositions for delivering a therapeutic gene product (e.g., IL-1 Ra) in a sustained manner to a location of interest, e.g., a joint.
• a therapeutic gene product e.g., IL-1 Ra
• the present invention also features methods and compositions for treating symptoms of conditions such as but not limited to osteoarthritis or rheumatoid arthritis.
• the present invention also features methods and compositions for providing an individual (e.g., a human) a therapeutically effective amount of a therapeutic gene product (e.g., IL-1 Ra).
• the methods and compositions may feature a recombinant self-complementary adeno-associated virus (sc-rAAV), wherein the sc-rAAV comprises an engineered capsid and a vector (an sc-rAAV vector) packaged within the capsid.
• the vector may comprise a transgene (e.g., a
• nucleotide sequence encoding a protein of interest, e.g., a therapeutic gene product, e.g., IL-1 Ra or a modified version thereof) operably linked to a promoter (e.g., a constitutive promoter).
• a promoter e.g., a constitutive promoter
• compositions comprising a recombinant self-complementary adeno-associated virus (sc-rAAVs) vector.
• a sc-rAAV vector is shown in SEQ ID NO: 1 of Table 1 below.
• the sc-rAAV vector of SEQ ID NO: 1 comprises a modified IL-1 Ra gene.
• the vector comprises SV40 polyadenylation sequences.
• the vector comprises bovine growth hormone (bGH) polyadenylation sequences.
• the vector comprises SV40 splice donor (SD) and splice acceptor (SA) sites.
• SD SV40 splice donor
• SA splice acceptor
• the sc-rAAV vectors comprise a nucleic acid that encodes a peptide of interest.
• the nucleic acid is at least 90% identical to SEQ ID NO: 2.
• the nucleic acid is at least 92% identical to SEQ ID NO: 2.
• the nucleic acid is at least 94% identical to SEQ ID NO: 2.
• the nucleic acid is at least 95% identical to SEQ ID NO: 2.
• the nucleic acid is at least 96% identical to SEQ ID NO: 2.
• the nucleic acid is at least 97% identical to SEQ ID NO: 2.
• the nucleic acid is at least 98% identical to SEQ ID NO: 2.
• the nucleic acid is at least 99% identical to SEQ ID NO: 2.
• SEQ ID NO: 3 is a sequence for a modified human IL-1 Ra that is about 98% identical to SEQ ID NO: 2
• SEQ ID NO: 4 is a sequence for a modified human IL-1 Ra that is about 99% identical to SEQ ID NO: 2
• Table 1 the bold letters in Table 1 are nucleotide substitutions as compared to SEQ ID NO: 2, and the codon underlined).
• the IL-1 Ra peptide encoded by the IL-1 Ra insert comprises IL-1 Ra (see SEQ ID NO: 6 in Table 2 below).
• the transgene (e.g., nucleotide sequence encoding protein of interest) is operably linked to a promoter.
• the promoter comprises the cytomegalovirus (CMV) promoter.
• CMV cytomegalovirus
• the present invention is not limited to the CMV promoter and may feature any appropriate promoter or portions of various promoters.
• promoters include CMV promoter, hybrid CMV promoter, CAG promoter, human beta-actin promoter, hybrid beta-actin promoter, EF1 promoter, U1 a promoter, 1M b promoter, a Tet-inducible promoter, a VP16-LexA promoter, chicken beta-actin (CBA) promoter, human elongation factor-1 alpha promoter, simian virus 40 (SV40) promoter, and herpes simplex virus thymidine kinase promoter.
• CBA chicken beta-actin
• SV40 simian virus 40
• the promoter comprises a hybrid promoter.
• Table 3 shows an IL-1 beta/IL-6 hybrid promoter (see also van de Loo et al., 2004, Gene Therapy 1 1 :581-590).
• the present invention is also not limited to the hybrid promoter shown in Table 3.
• the sc-rAAV vector is packaged within a capsid.
• the capsid comprises at least a portion of AAV serotype 1 (AAV1 ), AAV serotype 2, (AAV2), AAV serotype 3, (AAV3), AAV serotype 4, (AAV4), AAV serotype 5, (AAV5), AAV serotype 6, (AAV6), derivatives thereof, or
• the capsid comprises at least a portion of AAV serotype 2 and at least a portion of AAV serotype 6, e.g., AAV2.5.
• the composition e.g., the composition comprising the sc-rAAV, may be introduced into cells in a location of interest (e.g., in a human).
• the composition may be introduced into cells (e.g., chondrocytes, synoviocytes, e.g., type A, type B, etc.) in a joint via direct intraarticular injection.
• the composition is administered to a joint, synovium, subsynovium, joint capsule, tendon, ligament, cartilage, or peri-articular muscle of the human.
• the present invention is not limited to the aforementioned conditions (e.g., osteoarthritis), the means of administration (e.g., intraarticular injection), the location of interest (e.g., joint), or cell type (e.g., chondrocytes, synoviocytes).
• other cell types that may be transduced may include mesenchymal stem cells.
• the sc-rAAV transduces the vector into cells and the modified IL-1 Ra peptide is expressed.
• the IL-1 Ra peptide is expressed so as to provide the human with a therapeutically effective amount of said modified IL-1 Ra peptide effective for ameliorating symptoms associated with various conditions such as osteoarthritis or rheumatoid arthritis.
• introduction of the composition is performed once. In some embodiments, introduction of the composition (e.g., the sc- rAAV) is performed twice, e.g., a first time and a second time subsequent to the first time. In some embodiments, introduction of the composition is performed more than two times, e.g., three times, four times, five times, etc.
• the introduction of the composition a second time may be performed at a time point after the time when the method is first performed, e.g., after 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 1 1 months, 1 year, more than one year, etc.
• the composition may comprise any appropriate pharmaceutical composition.
• the composition comprises a buffered solution.
• the buffered solution comprises phosphate buffered saline (PBS).
• the composition further comprises sorbitol, e.g., 5% sorbitol.
• the composition further comprises a salt, e.g., NaCI.
• the concentration of salt may be any appropriate concentration, e.g., 350 mM NaCI, more than 350 mM NaCI, less then 350 mM, etc.
• the composition e.g., the sc-rAAV
• the secondary therapy comprises a therapeutic for OA or RA or any other appropriate therapy for treating the symptoms of the condition.
• Non-limiting examples of secondary therapies for OA include glucocorticoids, hyaluronan (viscosupplementation), platelet-rich plasma, and recombinant, human IL-1 Ra (Anakinra; Kineret®).
• the sc-rAAV is co-administered with glucocorticoids or platelet-rich plasma.
• Example 1 describes administration of a sc-rAAV of the present invention (encoding IL-1 Ra).
• the present invention is not limited to the disclosure of Example 1.
• Five patients enroll in a clinical trial investigating administration of a sc-rAAV of the present invention. The patients are as follows: (1 ) a 65 year old male with osteoarthritis in his right knee; (2) a 59 year old male with osteoarthritis in his left knee; (3) a 58 year old female with osteoarthritis in her left knee; (4) a 51 year old male with osteoarthritis in his right knee; and (5) a 48 year old male with
• IL-1 Ra is expressed in the chondrocytes and synoviocytes.
• Patient 1 describes amelioration of OA-related symptoms within 2 weeks.
• Patient 2 describes amelioration of OA-related symptoms within 1 week.
• Patient 3 describes amelioration of OA-related symptoms within 5 weeks.
• Patient 4 describes amelioration of OA-related symptoms within 1 week.
• Patient 5 describes no amelioration of OA-related symptoms.
• Example 2 describes a first administration of a sc-rAAV of the present invention (encoding IL-1 Ra) and a second administration of the same sc-rAAV of the present invention after a period of time.
• the present invention is not limited to the disclosure of Example 2.
• a 55-year-old male presents with osteoarthritis in his right knee.
• His physician performs a single intra-articular injection of the sc-rAAV vector of the present invention (encoding IL-1 Ra).
• the patient's symptoms are eliminated within 2 months.
• the physician administers a second (single) intraarticular injection of the same sc-rAAV vector (encoding IL-1 Ra) of the present invention.
• the patient's symptoms are still absent 6 months following the second injection.
• Example 3 describes a first administration of a sc-rAAV of the present invention (encoding IL-1 Ra) and a second administration of a sc-rAAV of the present invention (encoding IL-1 Ra) different from the first sc-rAAV after a period of time.
• the present invention is not limited to the disclosure of Example 3.
• a 49-year-old female presents with osteoarthritis in her right ankle.
• Her physician performs a single intra-articular injection of the sc-rAAV vector of the present invention (encoding IL- 1 Ra). The patient's symptoms have improved within 5 months but are not eliminated. After 6 months, the physician administers a second (single) intra-articular injection of a different sc-rAAV vector (encoding IL-1 Ra) of the present invention. Six months following the second injection, the patient's symptoms are eliminated.
• Example 4 describes co-administration of a sc-rAAV of the present invention (encoding IL-1 Ra) and a secondary therapy.
• the present invention is not limited to the disclosure of Example 4.
• a 68-year-old male presents with osteoarthritis in his left knee. His physician performs a single intra-articular injection of both a sc-rAAV vector of the present invention (encoding IL-1 Ra) and platelet-rich plasma. The patient's symptoms are eliminated within 2 months.
• references to the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting of, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting of is met.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Gastroenterology & Hepatology (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• Rheumatology (AREA)
• Virology (AREA)
• General Chemical & Material Sciences (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Toxicology (AREA)
• Physical Education & Sports Medicine (AREA)
• Dermatology (AREA)
• Cell Biology (AREA)
• Biomedical Technology (AREA)
• Microbiology (AREA)
• Developmental Biology & Embryology (AREA)
• Mycology (AREA)
• Pain & Pain Management (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=61197123

Family Applications (1)

Country Status (9)

Cited By (6)

Families Citing this family (2)

Citations (38)

Family Cites Families (25)

• 2017
  • 2017-08-18 JP JP2019530369A patent/JP7165410B2/ja active Active
  • 2017-08-18 KR KR1020197007510A patent/KR102759317B1/ko active Active
  • 2017-08-18 CA CA3073137A patent/CA3073137A1/en active Pending
  • 2017-08-18 KR KR1020237029234A patent/KR20230130155A/ko active Pending
  • 2017-08-18 AU AU2017313844A patent/AU2017313844B2/en active Active
  • 2017-08-18 CN CN201780061659.XA patent/CN109843306A/zh active Pending
  • 2017-08-18 WO PCT/US2017/047589 patent/WO2018035451A1/en not_active Ceased
  • 2017-08-18 EP EP17842207.7A patent/EP3500278B1/en active Active
  • 2017-08-18 ES ES17842207T patent/ES2982489T3/es active Active
  • 2017-08-18 US US16/326,488 patent/US11207382B2/en active Active
• 2021
  • 2021-12-17 US US17/555,320 patent/US20220175887A1/en active Pending
• 2022
  • 2022-07-11 JP JP2022111264A patent/JP7653150B2/ja active Active

Patent Citations (43)

Non-Patent Citations (34)

Also Published As

Similar Documents

Legal Events